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Abstract
Aim To assess the outcomes of rectal excisional proce-
dures in adults with chronic constipation.
Method Standardised methods and reporting of bene-
fits and harms were used for all CapaCiTY reviews that
closely adhered to PRISMA 2016 guidance. Main con-
clusions were presented as summary evidence statements
with a summative Oxford Centre for Evidence-Based
Medicine (2009) level.
Results Forty-seven studies were identified, providing
data on outcomes in 8340 patients. Average length of
procedures was 44 min and length of stay (LOS) was
3 days. There was inadequate evidence to determine vari-
ations in procedural duration or LOS by type of proce-
dure. Overall morbidity rate was 16.9% (0–61%), with
lower rates observed after Contour Transtar procedure
(8.9%). No mortality was reported after any procedures in
a total of 5896 patients. Although inconsistently
reported, good or satisfactory outcome occurred in 73–
80% of patients; a reduction of 53–91% in Longo scoring
system for obstructive defecation syndrome (ODS)
occurred in about 68–76% of patients. The most common
long-term adverse outcome is faecal urgency, typically
occurring in up to 10% of patients. Recurrent prolapse
occurred in 4.3% of patients. Patients with at least 3 ODS
symptoms together with a rectocoele with or without an
intussusception, who have failed conservative manage-
ment, may benefit from a rectal excisional procedure.
Conclusion Rectal excisional procedures are safe with
little major morbidity. It is not possible to advise which
excisional technique is superior from the point of view
of efficacy, peri-operative variables, or harms. Future
study is required.
Keywords surgery, constipation, rectal excision,
STARR, TRANSTAR
Introduction
Background and procedural variations
Chronic constipation is related to an inability to evacu-
ate the rectum in over half of all adults presenting for
specialist advice. This phenomenon, which may be vari-
ably described as obstructed defaecation or rectal evacu-
ation disorder (and many other terms) is characterized
by excessive straining, the feeling of incomplete evacua-
tion, post-defaecatory seepage and often mucous dis-
charge and pelvic pain [1]. In some of these patients,
there is clinical and radiological (usually proctographic)
evidence of a dynamic structural abnormality, leading
to physical impediment to emptying during defaecation.
The most common abnormalities are rectocoele and/or
intussusception. Theoretically, these anatomical variants
could lead to the features of obstructed defaecation by
a process of loss of force vector (ballooning of the rec-
tum into a rectocoele or invagination of the rectum
into an intussusception, rather than evacuation of stool
on straining) or mucosal obstruction (in the case of an
intussusception) [1]. Correction of these variants can
be carried out by surgically excising the redundant rec-
tal wall, i.e. that ballooning out or prolapsing in, thus
restoring ‘normal’ anatomy.
Techniques
The stapled transanal rectal resection (STARR) proce-
dure uses two circular procedure for prolapsing
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haemorrhoids (PPH)01 stapling devices (Ethicon Endo-
surgery, INC., Cincinnati, Ohio, USA), or at times,
two circular PPH03 devices. They are used sequentially
to remove the anterior rectal wall prolapse and then the
posterior rectal wall prolapse. These full thickness rectal
wall excisions result in defects that are anastomosed
with staples contained within the device. The STARR
procedure was derived from the technique of stapled
haemorrhoidopexy and was introduced into clinical
practice by Antonio Longo using the PPH01 device
[2]. Initially, most STARR procedures were performed
with PPH01; however, subsequently the PPH03 device
was developed, essentially for haemorrhoidopexies, to
reduce intra-operative staple line bleeding. The two
devices, PPH01 and PPH03, differ only with respect to
the closed staple height, which varies between 1–
2.5 mm and 0.75–1.5 mm, respectively. The PPH03
device is no longer licensed for use for STARR because
of concerns that the staple line height was insufficient
for the thickness of tissue that was resected and anasto-
mosed. As with all new techniques, in order to ensure
that safety and efficacy concerns were addressed, a num-
ber of initiatives were put in place by the manufacturer.
The procedure could only be performed by trained sur-
geons who then mentored other surgeons. In the UK,
the PPH01 device is no longer used for haemor-
rhoidopexies, and consequently Ethicon will only per-
mit the sale of this device to institutions with surgeons
trained in the STARR technique. The European
STARR registry was established through collaboration
between Ethicon Endosurgery and the colorectal soci-
eties in the UK, France, Germany and Italy. Outcomes
from this registry have been published and, in response,
the National Institute for Health and Care Excellence
(NICE) issued interventional procedure guidance in
2010. The NICE guidance concluded that ‘the current
evidence on safety and efficacy of stapled transanal rec-
tal resection (STARR) for obstructed defaecation syn-
drome (ODS) is adequate . . . . . . the procedure may
therefore be used with normal arrangements for clinical
governance, consent and audit.’ [www.nice.org.uk/
ipg351].
Despite its proven safety and efficacy, the STARR
procedure still had limitations. These were primarily
related to the stapling device itself. The two biggest
concerns were that the rectal resection was performed
‘blind’ within the low rectum and that the volume of
the resected tissue was entirely dependent upon the
capacity of the stapling device housing, rather than the
extent of the prolapse. As such, the surgeon was
unable to modify the extent of resection in relation to
the size of the prolapse. Consequently, a new stapling
device, the Contour Transtar curved cutter stapler
(Ethicon Endosurgery, INC.), was introduced [3] in
order to allow a tailored correction of the prolapse by
removing more tissue. It would also allow this resec-
tion to be performed under direct vision. The Contour
Transtar stapler utilises replaceable staple cartridges
allowing multiple firings with a single device.
Although STARR has been heavily popularized, it is
not the first procedure to use of rectal excision as a
means of treating prolapse. Edward Delorme originally
described his procedure for full-thickness external rectal
prolapse in 1900 [4]. There have been several modifica-
tions, one being an intra-anal Delorme’s procedure for
the treatment of recto-anal intussusception [5]. Unlike
STARR and Contour Transtar, there is no full-thickness
rectal wall excision and only the redundant mucosa is
excised. The mucosa is stripped cephalad, and the
underlying muscle is plicated together with sutures to
concertina the prolapse.
Scope
The purpose of this review was to assess the efficacy
and harms of rectal excisional procedures for internal
prolapse and/or rectocoele in adults. Procedures con-
sidered beyond the scope of systematic review included:
(i) those where ‘tightening’ is effected without excision
(covered in rectovaginal reinforcement systematic
review); (ii) those where only mucosa is excised (muco-
sectomy) and there is no plication of the muscular wall;
(iii) those where a mucosectomy and plication are lim-
ited to the anterior wall (covered in rectovaginal rein-
forcement systematic review); (iv) those where the
whole rectum is resected rather than a component of
the wall, i.e. as occasionally performed for megarectum
[6]. Studies where outcomes could not be segregated
by eligible procedure were also excluded, due to a
mixed patient population with internal and external rec-
tal prolapse, mixed indications, including numerous pel-
vic floor abnormalities or limited postoperative
outcomes, transanal endocopic microsurgery proce-
dures, technical reports, or cost analyses only.
Previous reviews
One previous meta-analysis including 26 studies [7]
addressed the outcome of rectal excisional procedures
for constipation.
Summary of search results and study
quality
The search yielded a total of 84 articles for full text
review (Fig. 1). From these, 47 published between
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2000 and 2014 contributed to the systematic review,
providing data on outcomes in a total of 8340 patients
(range 20–2224 patients per study) (Table 1). Specific
exclusions after full-text review (and after exclusion of
non-English language publications) included nine stud-
ies where the population sample was confirmed to be
< 20 patients, eight where follow-up was < 12 months;
five studies with out of scope procedures [8–11], three
studies where data were considered duplicate [12,13],
and three where outcomes could not be segregated by
eligible procedure. Other exclusion criteria were: indica-
tion not constipation (n = 1) and lack of extractable
outcome data (n = 5).
The quality of studies varied. The 47 included stud-
ies (Table 1) included 42 observational studies and five
randomised controlled trials (RCTs). The latter
included three good quality RCTs (level IB) with low
levels of predicted bias, and two with less well described
methodology (level IIB). The remaining 42 observa-
tional studies encompassed several good quality
prospective cohort studies with low levels of bias includ-
ing four prospectively maintained funded registries
(level IIB). Other studies were a mix of prospective and
retrospective case series. Mean study follow-up was
1.9 years (range 1.0–5.5 years); 36 studies originated
from European centres, three from the USA and eight
from other countries.
Perioperative data
Perioperative data were reported by 47 studies reporting
55 procedures (Tables 2 and 3). Measures of variation
of continuous measures included ranges or standard
deviations but were inconsistently reported. Average
procedural duration and length of stay (LOS) varied
between procedures but design heterogeneity, small
numbers of studies and large range of values precluded
any clear conclusions (Table 3). The overall average
duration of procedures reported by cohorts was 44
(range 23–95) min, and the overall average LOS was
3.0 (range 1.0–8.0) days (Figs 2 and 3). In one RCT
of 100 patients (STARR vs Contour Transtar) [37],
Contour Transtar took significantly longer to perform
(52.2 vs 42.4 minutes P = 0.008). However this reduc-
tion was not apparent more broadly within the pooled
findings (Fig. 2). While LOS for intra-anal Delorme’s
procedure was shorter (2 days) this was based on only
one study reporting this outcome in 34 patients.
Figure 1 PRISMA diagram of search results.
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Table 1 All studies included in systematic review.
Author Year Centre Country Total N FU* Design Level†
Liberman [14] 2000 Omaha USA 34 43 RCS IV
Boccasanta [15] 2004 Milan Italy 50 23 RCT IB
Boccasanta [16] 2004 Milan Italy 90 16 PCH IIB
Pescatori [17] 2006 Rome Italy 26 36 RCS IV
Arroyo [18] 2007 Elche Spain 37 24 PCH IIB
Gagliardi [19] 2008 Multicentre Italy 85‡ 17 RCS IV
Dindo [20] 2008 Zurich Switzerland 24 18 PCH IIB
Lehur [21] 2008 Multicentre France, Italy, UK 119 12 RCT IIB
Arroyo [22] 2008 Multicentre Spain 104 26 PCH IIB
Lenisa [3] 2009 Multicentre Europe 75 12 PCH IIB
Harris [23] 2009 Orlando USA 75 12 RCH IV
Jayne [24] 2009 Multicentre UK, Germany, Italy 2224§ 12 PCH IIB
Reboa [25] 2009 Genoa Italy 33 18 PCH IIB
Boccasanta [26] 2010 Milan Italy 142 24 PCH IIB
Isbert [27] 2010 Nuremberg Germany 150 12 RCH IIB
Zhang [28] 2010 Beijing China 50 12 PCH IIB
Madbouly [29] 2010 Alexandria Egypt 46 42 PCH IIB
Schwandner [30] 2010 Regensburg Germany 379 12 PCH IIB
Ram [31] 2010 Ramat Aviv Israel 30 26 PCS IV
Zehler [32] 2010 Hamburg Germany 20 66 PCS IV
Goede [33] 2011 Bristol UK 344 12 PCS IV
Meurette [34] 2011 Nantes France 30 48 PCS IV
Martellucci [35] 2011 Siena Italy 133 19 PCS IV
Patel [36] 2011 Houston Texas 37 20 PCH IIB
Boccasanta [37] 2011 Milan Italy 100 36 RCT IB
Stuto [38] 2011 Pordenone Italy 2171 12 PCH IIB
Song [39] 2011 Seoul South Korea 58 34 RCH IV
Ding [40] 2011 Beijing China 86 12 PCH IIB
Renzi [41] 2011 Naples Italy 61 24 RCT IB
Reibetanz [42] 2011 Wuerzburg Germany 170 18 RCH IIB
Naldini [43] 2011 Pisa Italy 30 24 PCH IIB
Biviano [8] 2011 Rome Italy 60 38 PCH IIB
Savastano [44] 2012 Vicenza Italy 64 27 PCH IIB
Jiang [45] 2012 Wuhan China 43 12 RCS IV
Boenicke [46] 2012 Wuerzburg Germany 181 19 PCH IIB
Kohler [47] 2012 Dresden Germany 80 39 PCS IV
Hasan [48] 2012 Cairo Egypt 40 12 PCH IIB
Ganio [49] 2013 Vercelli Italy 167 36 RCS IV
Adams [50] 2013 London UK 37 13 RCS IV
Masoni [51] 2013 Rome Italy 187 12 RCS IV
Bock [52] 2013 St Gallen Switzerland 70 48 RCS IV
Zhang [53] 2013 Beijing China 75 30 PCH IIB
Panicucci [54] 2014 Pisa Italy 54 12 PCH IIB
Borie [55] 2014 Nimes France 52 18 RCH IV
Ribaric [56] 2014 Multicenter Europe 100 12 PCH IIB
Gentile [57] 2014 Naples Italy 66 12 RCT IIB
Leardi [58] 2014 L’Aquila Italy 51 36 PCS IV
RCS, retrospective cohort study; PCS, prospective case series; RCT, randomised controlled trial; PCH, prospective cohort study.
*Mean follow up in months.
†Oxford CEBM [13].
‡Report on 123 patients, but only 85 operated on.
§Report on 2838 patients for complications, 2224 reached 12 months follow-up.
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Table 2 Perioperative data by procedure.
Author Year N
Time
(minutes) LOS (days)
Post-op
bleed
Req.
Treatment %
Sepsis
%
Post-op
anastomotic
dehiscence
%
Total
complications
%
Mortality
%
(a) PPH-01
Boccasanta [15] 2004 25 41.8  6 2.1  0.8 4 0 0 40 0
Boccasanta [16] 2004 90 43.3  9 2.1  0.8 4.4 0 0 16.5 0
Arroyo [18] 2007 17 45.9 (9.8) NR 6 0 0 NR 0
Gagliardi [19] 2008 85 † NR NR 2.3 3 0 18 0
Dindo [20] 2008 24 60 (40–110) 3 (1–10) 4.1 0 0 25 0
Lehur [21] 2008 119 40 (15–56) 2.1 (1–6) 1.8 1.8 0 15 0
Arroyo [22] 2008 37‡‡ 46.7 (9.3) 2.2 (0.7) 2.8 0 0 NR 0
Boccasanta [26] 2010 74 35.8  6.1 2.6  0.5 4 0 0 28.3 0
Harris [23] 2009 36 52.7 2.6 19.4§§ 2.8 0 61.1¶¶ 0
Isbert [27] 2010 68 57  15.4 3.4  1.6 3 0 2 7.3 0
Jayne [24] 2009 2224‡ 44 (15–210) 3.7 (1–36) 5 4.4 3.5* 36 0
Reboa [25] 2009 33 37  7 1.5  0.6 0 0 0 15.1 0
Zhang [28] 2010 50 28 NR 0 0 0 NR 0
Madbouly [29] 2010 46 48.4  9.6 1 0 0 0 15.2 0
Schwandner [30] 2010 379 40 5.5 2.9 1.6 7.1* 21.2 0
Ram [31] 2010 30 40 (35–80) 2 (1–4) 0 0 NR 36.7 0
Zehler [32] 2010 20 53.5 (45–65) 8 (3–22) 15 0 0 20 0
Goede [33] 2011 344 NR NR 2.7 NR NR 16.3 0
Meurette [34] 2011 30 40  8 3  1 NR NR NR 27 0
Patel [36] 2011 37 NR 1 0 NR NR 35.1 0
Boccasanta [37] 2011 50 42.4 (6.9) 3.2 (0.6) 2 0 0 4 0
Stuto [38] 2011 2171¶ 95 (15–230) 3.6 (1–21) NR NR NR NR NR
Song [39] 2011 58 35.1  11.3 3.91  0.84 4 0 NR NR 0
Ding [40] 2011 86 30  7 5  1.8 0 0 0 NR 0
Renzi [41] 2011 30 28.1 (11.5) 1.2 (0.5) 6.6 0 NR NR 0
Reibetanz [42] 2011 170§ NR NR 0 0 0.6 7 0
Naldini [43] 2011 15 NR 3.4 (3–6) 0 NR NR 0 0
Biviano [8] 2011 30 NR NR 0 0 0 6 0
Savastano [44] 2012 32 28 (20–45) 2 (1–3) 13 0 0 NR 0
Boenicke [46] 2012 181** NR NR 1 0 0.5 8.2 0
Kohler [47] 2012 80 67 (34–182) NR 6 1 1 22.5 0
Hasan [48] 2012 40 35  10 1.7  2.3 0 0 0 NR 0
Adams [50] 2013 37 NR 1 (0–8) 5.4 2.7 0 32 0
Zhang [53] 2013 75 NR NR 0 0 0 NR 0
Panicucci [54] 2014 54 †† NR NR NR NR NR NR NR
Borie [55] 2014 25 NR 5.6  2.1 0 0 0 24 0
Leardi [58] 2014 51 NR 3 2 0 0 2 0
(b) PPH03
Arroyo [18] 2007 20 40.1 (10.4) NR 0 0 0 NR 0
Arroyo [22] 2008 67*** 46.7 (9.3) 2.2 (0.7) 2.8 0 0 NR 0
Jiang [45] 2012 43 23  4 5 (4–6) 0 0 0 NR 0
Gentile [57] 2014 30 40 NR NR NR NR 20 NR
(c) Contour Transtar
Lenisa [3] 2009 75 45 (24–90) 4 (1–16) 2.6 0 0 7 0
Isbert [27] 2010 82 51  18.2 3.6  2.3 3 0 0 7.5 0
Martellucci [35] 2011 133 42 (26–71) NR 1.5 NR 1.5 15.7 0
Boccasanta [37] 2011 50 52.2 (8.7) 3.5 (1.0) 2 0 0 2 0
Renzi [41] 2011 31 33.1 (15.7) 1.25 (0.5) 3.2 0 NR NR 0
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Summary evidence statements: perioperative data
1 The average duration of procedures was 44 min,
although this ranged widely between studies from 23
to 95 min (level II).
2 The average length of stay was 3 days although this
ranged widely between studies from 1 to 8 days
(level II).
3 There was inadequate evidence to determine varia-
tions in procedural duration or length of stay by type
of procedure (level IV).
Harms
Perioperative complications
Five measures of perioperative harm were reported by a
majority of studies within the review. In general, there was
considerable heterogeneity between cohort findings. This
heterogeneity may have reflected (for example) differing
inclusion, procedural content, context of care, or thresh-
olds or conventions for recording complications.
Overall procedural complication rates varied between
cohorts from 0% to 61% Fig. 4. Random effects meta-
analysis found the overall complication rate to be 16.9%
(95% CI: 12.7–21.5%), I2 = 93%. The Contour Transtar
procedure reported a lower overall complication rate of
8.9% (95% CI: 5.1–13.5%), I2 = 70%, although cohort
findings within this category were heterogeneous and
non-comparative. The two RCTs (IB) comparing STARR
to Contour Transtar reported no difference in periopera-
tive complication rates [37,41], although these included
only 161 patients in total and six events. A more general-
isable estimate of the overall complication rate may come
from the European STARR registry which reported an
overall morbidity rate of 36% from 2838 patients [24].
The inclusion criteria for morbidity in this registry incor-
porated urgency (20%), but this was not universally
applied in most other studies, explaining its discrepancy
from the pooled findings.
Rates of post-operative bleeding requiring treatment
varied between cohorts from 0% to 19% (Fig. 5). Ran-
dom effects meta-analysis found the pooled bleed rate
to be 1.6% (95% CI: 0.9–2.5%), I2 = 63%. Regarding
Table 2 (Continued).
Author Year N
Time
(minutes) LOS (days)
Post-op
bleed
Req.
Treatment %
Sepsis
%
Post-op
anastomotic
dehiscence
%
Total
complications
%
Mortality
%
Naldini [43] 2011 15 NR 3.1 (2–5) 3.3 NR NR 3.3 0
Savastano [44] 2012 32 43 (32–65) 4 (3–7) 6 0 9.3 NR 0
Masoni [51] 2013 187 48 (32–78) < 3 0 0 0 7.4 0
Bock [52] 2013 70 NR NR 0 0 0 23 0
Ribaric [56] 2014 100 43.8  13.9 4.36  2.75 1 0 0 11 0
(d) Intra-anal Delorme’s procedure
Liberman [14] 2000 34 NR 1.8 (2.4) 3 8.8 0 35.3 0
Pescatori [17] 2006 26 NR NR 15.4 16††† 12.5††† 45††† 0
Ganio [49] 2013 167‡‡‡ NR NR 0 1.2 1.8 10.2 0
Gentile [57] 2014 36 65 NR NR NR NR 19.4 0
NR, not recorded.
All PPH03, except Jiang [45] translinear stapler.
*Reported as staple line complications, including dehiscence.
†Report on 123 patients, but only 85 operated on.
‡Report on 2838 patients for complications, 2224 reached 12 months follow-up.
§101 patients had Countour Transtar.
¶208 patients had Contour Transtar.
**Some patients had Contour Transtar.
††18 patients had Contour Transtar.
‡‡Complications are reported for 104 patients (67 had PPH03).
§§It is uncertain if this required intervention as recorded as ‘rectal bleeding’.
¶¶Total complications included tenesmus, diarrhoea, faecal incontinence, and pruritis ani.
***Complications are reported for 104 patients (37 had PPH01); NR: not recorded.
†††These percentages are based upon analysis of 40 patients (14 patients having had PPH01 or PPH01 with manual mucosectomy).
‡‡‡91 patients also had levatoroplasty.
ª 2017 The Authors. Colorectal Disease published by John Wiley & Sons Ltd
on behalf of Association of Coloproctology of Great Britain and Ireland. 19 (Suppl. 3), 49–7254
Rectal excision for constipation M. Mercer-Jones et al.
intra-operative bleeding from staple lines, results from
one prospective cohort study (IIB) showed that less
intraoperative staple line sutures were required with
PPH03 compared with PPH01 [18]. Details of treat-
ments provided (e.g. transfusion or re-operation) were
unclear in many instances.
Sepsis rates varied from 0% to 16%, but were consis-
tently low, occurring in no patients in 78% of cohorts
reported. Random effects meta-analysis found the sepsis
rate to be 0.2% (95% CI: 0.0–0.7%), I2 = 63%. Septic
complications were mostly related to urinary tract
infections, C. difficile infection, or more rarely, pneu-
monia. Sepsis rates for Delorme’s procedure appeared
high at 6.2% (95% CI: 0.0–19.4%), I2 = 82%, but find-
ings from the three studies were highly heterogeneous
and the only moderately large study [49] reported a
1.2% sepsis rate. The rate of post-operative anastomotic
dehiscence (wound rupture) varied between cohorts
from 0% to 13% but was consistently low, occurring in
no patients in 76% of cohorts reported. Random effects
meta-analysis found the pooled rate of anastomotic
dehiscence to be 0.3% (95% CI: 0.0–0.8%), I2 = 62%.
Table 3 Procedural data.
Procedure
Procedure duration (mins) Length of stay (days) Follow-up (months)
N Mean Range N Mean Range N Mean Range
PPH-01 25 44.6 (28.0–95.0) 25 2.9 (1.0–8.0) 37 23.0 (12.0–66.0)
PPH-03 4 37.5 (23.0–46.7) 2 3.6 (2.2–5.0) 4 18.5 (12.0–26.0)
Contour Transtar 8 44.8 (33.1–52.2) 7 3.4 (1.3–4.4) 10 22.6 (12.0–48.0)
Delorme’s 1 65.0 – 1 1.8 – 3 38.3 (36.0–43.0)
Total 37 43.8 (23.0–95.0) 35 3.0 (1.0–8.0) 54 23.5 (12.0–66.0)
Figure 2 Forest plot showing procedure
duration by operation type.
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There was inadequate evidence to select between proce-
dures on the basis of individual complications.
No deaths were reported in any cohort of patients
reporting mortality, which included a total of 5896
patients (Table 3). Incidences of serious complications
were reported but these were rare. These included: one
case of sepsis with retropneumoperitoneum [19], two
cases of intra-operatively recognized rectal perforation
requiring diverting colostomy [32,35], one case of rec-
tovaginal abscess requiring diversion [50], one case of
suture line disruption requiring diversion [30], and one
case of rectal necrosis requiring a colostomy [24]. There
were no cases of inadvertent small bowel injury as a
result of peritoneal inclusion with anterior rectal wall
excision and enterocoele excision. This is despite the
fact that in one study [42], 84 of 101 patients who had
Contour Transtar, and 14 of 69 patients who had
PPH01, had peritoneum present in the resected tissue.
Long-term adverse outcomes
Although obstructed defecation is a benign condition,
it may have a significant impact on a patient’s quality
of life. Studies have consistently reported a number of
long-term conditions and symptoms occurring after
stapled rectal excision procedures that may have a fur-
ther negative impact upon quality of life. Measures
reported by more than half of cohorts include: rectal
stenosis (83% of cohorts), recto-vaginal fistula (76%),
pain/proctalgia (70%), and urgency after defaecation
(72%); those less consistently reported include recur-
rent prolapse (46%) and dyspareunia (33%) (Table 4).
Random effects meta-analysis found that reported
rectal stenosis rates were 0.2% (95% CI: 0.0–0.6%),
I2 = 30%, although individual cohorts varied from 0.0%
to 7.4%, with no stenosis reported in 67% of cohorts.
Recto-vaginal fistula was a very rare outcome, occurring
in just 3 of 4851 patients (0.062%) studied. Rectal pain
or proctalgia lasting > 6 months post-procedure was
reported by 0.7% of patients (95% CI: 0.1–1.6%),
I2 = 79%, although individual cohorts varied from 0%
to 17%, with no proctalgia reported in 53% of cohorts.
Similarly to pooled findings, there was no difference in
pain comparing STARR and Contour Transtar in the
two level 1B RCTs [37,41]; at 36 months, the inci-
dence of pain was significantly less compared with pre-
Figure 3 Forest plot showing length of
stay by operation type.
ª 2017 The Authors. Colorectal Disease published by John Wiley & Sons Ltd
on behalf of Association of Coloproctology of Great Britain and Ireland. 19 (Suppl. 3), 49–7256
Rectal excision for constipation M. Mercer-Jones et al.
operative values in both groups [37]. The two studies
with the highest reported incidence of proctalgia were
both PCHs (IIB). At 38  18 months post-STARR
(n = 30), 17% complained of intermittent anal pain,
however despite the fact that pre-operative Cleveland
Clinic Constipation scores were recorded, there was no
analysis about de novo pain [8]. At 12 months post-
STARR (n = 2838), 7.1% complained of persistent pain
[24]. Again there was no analysis regarding the de novo
nature of this pain.
Urgency of defecation, at least one year post-proce-
dure, was reported by 5.2% of patients (95% CI: 2.7–
8.2%), I2 = 92%, although findings were heterogeneous
and individual cohorts varied from 0% to 34% (Fig. 6).
The European STARR registry reported higher urgency
rates of 20% at 12 months [24] and the German
STARR registry reported rates of 25% at 12 months
[30]. Both groups of authors pointed to poor record-
ing of pre-operative urgency symptoms, relying on the
subset scores from patients’ Symptom Severity Score
(SSS). Schwander et al.[30] suggest that this high
incidence reflected numbers with new onset urgency
with a score of > 1 in SSS, 5.5% had score > 3, and
8% of patients observed a reduction in urgency com-
pared with pre-op. Jayne et al. [24] acknowledged in a
subsequent reply to an invited expert’s analysis of their
paper, that de novo urgency was not recorded in their
registry but 20% of patients reported this as a compli-
cation. Analysis of the subset question in their SSS
suggested that 39.9% of patients experienced urgency
pre-operatively and this fell to 26.8% at 12 months
post-STARR. The highest reported incidence of
urgency came from an RCT (IB) comparing STARR/
PPH01 (34% at 3 years) with Contour Transtar (14%
at 3 years) (P = 0.035) [37]. Urgency was reported as
being de novo in both groups. However, the text in
the results reports that the symptoms resolved in all
but one patient (it is probable that this refers to tenes-
mus which is reported for one patient post-op). The
other RCT (level IB) comparing STARR/PPH01 with
Contour Transtar showed no difference in urgency
rates after 24 months [41].
Figure 4 Forest plot showing rates of
complications by operation type.
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Summary evidence statements: harms
1 Evidence is largely drawn from observational stud-
ies and comparisons. Findings were heteroge-
neous, making estimates tentative and imprecise
(level IV).
2 Overall procedural complication rates ranged from 0%
to 61%. However, these complications may typically
occur in about 13–22% of procedures (level II).
3 The Contour Transtar procedure may feature a
lower overall complication rate although this needs
to be confirmed with better research (level IV).
4 Post-operative bleeding requiring treatment may
typically occur in 1–3% of patients (level II).
5 Post-operative sepsis and anastomotic dehiscence
are rare complications rare typically occurring in less
than 1% of patients (level II).
6 Serious acute post-operative complications are very
rare occurring in about one in a thousand patients
(level II).
7 In the longer term (12 months or more), rectal
stenosis is a rare complication typically occurring in
less than 1% of patients (level II).
8 The most common longer term adverse outcome is
urgency of defaecation, typically occurring in up to
10% of patients (level II).
9 Longer term pain is experienced typically by less
than 2% of patients (level II).
Figure 5 Forest plot showing rates of
bleeding by operation type.
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Table 4 Long-term adverse outcomes after rectal excisional procedures.
Author Year N Stenosis
Recto
vaginal
fistula
Recurrent
Prolapse
Pain/
proctalgia > 6
months Dyspareunia
Urgency
after 12
months
(a) PPH01
Boccasanta [15] 2004 25 4 0 0 0 0 0
Boccasanta [16] 2004 90 3.3 0 0 0 0 1.1
Arroyo [18] 2007 17 6 0 6 0 NR 0
Gagliardi [19] 2008 85* 0 0 9.4 1.1 1.1 8.2
Dindo [20] 2008 24 0 0 NR 4.1 0 NR
Lehur [21] 2008 119 0 0 NR 1.8 0 NR
Arroyo [22] 2008 37†† 0 0 5.7 0.9 NR 5.8
Harris [23] 2009 36 0 0 2.7 2.7 10.5 16.7E
Jayne [24] 2009 2224† 0.6 0.04 NR 7.1 0.1 20
Reboa [25] 2009 33 0 0 NR 0 NR 6
Boccasanta [26] 2010 74 1.3 0 0 0 0 2.7
Isbert [27] 2010 68 0 0 2.9 3 NR 4.4
Zhang [28] 2010 50 0 0 2 2 0 2
Madbouly [29] 2010 46 6.5 0 NR 0 NR 0
Schwandner [30] 2010 379 2.1 NR NR 0.5 NR 25.3§§
Ram [31] 2010 30 NR NR NR 0 NR NR
Zehler [32] 2010 20 0 0 NR NR NR NR
Goede [33] 2011 344 2.9 NR NR NR NR 11.5***
Meurette [34] 2011 30 NS NR NR 0 NR 6.8
Patel [36] 2011 37 2.7 NR NR NR 5.4 NR
Boccasanta [37] 2011 50 0 0 12 0 NR 34¶¶
Stuto [38] 2011 2171§ NR NR NR NR NR NR
Song [39] 2011 58 1.7 NR NR 0 NR 0
Ding [40] 2011 86 0 0 NR 0 NR 0
Renzi [41] 2011 30 NR 0 NR NR 3.3 10
Reibetanz [42] 2011 170‡ 0 0 NR 0 NR NR
Naldini [43] 2011 15 NR NR NR NR NR 20
Biviano [8] 2011 30 0 0 3 17 0 6
Savastano [44] 2012 32 6.25 0 NR 0 0 0
Boenicke [46] 2012 181¶ 0 0 NR 0 NR NR
Kohler [47] 2012 80 0 0 5 0 NR 12.5
Hasan [48] 2012 40 0 0 0 2.5 NR 2.5
Adams [50] 2013 37 2.7 0 5.4 NR NR NR
Zhang [53] 2013 75 0 0 4 NR NR 1.3†††
Panicucci [54] 2014 54** NR NR NR NR NR 7.4
Borie [55] 2014 25 0 0 NR NR 12‡‡ NR
Leardi [58] 2014 51 0 0 2 NR NR 0
(b) PPH03
Arroyo [18] 2007 20 0 0 5 0 NR 0
Arroyo [22] 2008 67‡‡‡ 0 0 5.7 0.9 NR 5.8
Jiang [45] 2012 43 0 0 NR 2 NR NR
Gentile [57] 2014 30 NR NR NR NR 16.6 NR
(c) Contour Transtar
Lenisa [3] 2009 75 0 0 NR 0 NR 13
Isbert [27] 2010 82 0 0 0 3 NR 4.8
Martellucci [35] 2011 133 0 0.8 NR 1.5 NR 6.8
Boccasanta [37] 2011 50 0 0 0 0 0 14
Renzi [41] 2011 31 NR NR NR NR 0 9.6
Naldini [43] 2011 15 NR NR NR NR NR 13
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10 Rectovaginal fistula is a very rare longer term
complication, occurring in about one in about one
in every one thousand six hundred patients (level
II).
11 There was insufficient evidence to establish whether
specific post-operative or longer term complications
varied between procedures (level IV).
12 In all studies where mortality was recorded, there
were no deaths in a total of 5896 patients studied
(level II).
Efficacy
Measurement of clinical outcome was consistently
recorded in many studies using a variety of the available
subjective summative scoring instruments for constipa-
tion symptoms (Table 6). These included the Cleveland
Clinic Constipation Score (21 studies), obstructed defe-
cation syndrome (ODS) score (30 studies), Symptom
Severity Score (SSS) (eight studies).
The Longo scoring system for ODS was reported for
56% of cohorts. Reduction in ODS occurred in 72.2%
of patients (95% CI: 68.5–75.8%), I2 = 83% (Fig. 7).
There was considerable heterogeneity between findings,
which varied from 53–91% and may reflect multiple
causes. Although findings are imprecise, there was no
robust evidence that one procedure produced greater
score reductions than another. Improvement in consti-
pation was reported in all studies where it was recorded.
In many publications regarding surgical treatment of
constipation, success has been defined as > 50%
improvement in objective scores. A total of 18/21 stud-
ies reported > 50% improvement in CCS; all studies
(30/30) reported > 50% improvement in ODS; 5/8
studies reported > 50% improvement in SSS. Significant
improvement in ODS was seen in both arms of the two
RCTs (IB) comparing STARR (PPH01) and Contour
Transtar [37,41] and in the other level IB RCT com-
paring STARR with PPH01 and mucosectomy (with
PPH01) together with levatoroplasty [15]. Whilst this
Table 4 (Continued).
Author Year N Stenosis
Recto
vaginal
fistula
Recurrent
Prolapse
Pain/
proctalgia > 6
months Dyspareunia
Urgency
after 12
months
Savastano [44] 2012 32 0 0 NR 0 0 3.2
Masoni [51] 2013 187 0 0.5 NR NR NR 0
Bock [52] 2013 70 0 NR 8.6 NR NR 0
Ribaric [56] 2014 100 0 0 NR 1 NR 3
(d) Intra-anal Delorme’s procedure
Liberman [14] 2000 34 3 0 3 0 NR NR
Pescatori §§§ [17] 2006 26 7.5 0 35 2.5 NR NR
Ganio [49] 2013 167 ¶¶¶ 1.8 0 5.4 2.4 NR NR
Gentile [57] 2014 36 NR NR NR NR 11.1 NR
NR, not recorded.
All PPH03, except Jiang [45] translinear stapler.
*Report on 123 patients, but only 85 operated on.
†Report on 2838 patients for complications, 2224 reached 12 months follow-up.
‡101 patients had Countour Transtar.
§208 patients had Contour Transtar
¶Some patients had Contour Transtar
**18 patients had Contour Transtar.
††Complications are reported for 104 patients (67 had PPH03).
‡‡Not stated if de novo.
§§This reflects numbers with score of > 1 in Symptom Severity score, 5.5% had score > 3, and 8% of patients observed a reduction
in urgency compared with pre-op.
¶¶Table refers to this incidence at 3 years, however text reports that all urgency resolved in all but one patient.
***Authors report that 74% of patients had pre-op urgency.
†††Uncertain if this is de novo.
‡‡‡Complications are reported for 104 patients (37 had PPH01).
§§§These percentages are based upon analysis of 40 patients (14 patients having had PPH01 or PPH01 with manual mucosec-
tomy).
¶¶¶91 patients also had levatoroplasty.
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improvement was maintained at three years, without
difference between procedures in one trial [37], in the
other at 24 months the improvement was maintained in
the Contour Transtar group but not in the STARR
group and there was a significant difference in scores
between the two groups [41]. In the other two RCTs
of lesser quality (IIB), STARR (PPH01) was shown to
be significantly better for functional outcome compared
with biofeedback (although there was > 50% attrition
rate in the biofeedback group) [21], and STARR
(PPH01) was shown to give similar functional results
compared with Intra-anal Delorme’s with levatoroplasty
[57]. In other non-randomised (level IIB) comparisons
of STARR (PPH01) vs Contour Transtar [8,27,43]
there was no difference in functional outcome. One
prospective cohort study (level IIB) compared PPH01
with PPH03 [18] and showed no difference in func-
tional outcome, and a further compared STARR with
macrogol therapy [8]. There was no difference in out-
come when looking at response rates, however it was
unclear if groups were matched and no report on differ-
ent laxative use was included in inclusion criteria. One
would normally assume that macrogol or other medical
management would have been tried before selecting a
patient for a rectal excisional procedure.
The effect of time post-procedure and efficacy was
examined in the four level I/IIB studies with a follow-
up of > 30 months [8,37,53,57]. Three studies showed
greater than 75% reduction in subjective scores
[8,37,57] and the other greater than 50% reduction,
regardless of the procedure provided.
Global ‘success’ or ‘satisfaction’ ratings (GSR) were
obtained via a variety of methods in 28 of 55 cohorts
(Table 5), where ‘satisfied’ or ‘very satisfied’, ‘good’,
‘very good’ and ‘excellent’ were interpreted as positive
outcomes. Further studies also reported individual
symptoms. No study reported acquiring data objectively
using personnel not involved in the surgical care of the
patient or data collection blind to intervention status.
Most reports assert that the majority of patients
Figure 6 Forest plot showing rates of
rectal urgency after 12 months by
operation type.
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undergoing PPH01, PPH03, Contour Transtar, and
intra-anal Delorme’s procedure were satisfied. Random
effects meta-analysis found the global satisfaction rating
to be 76.3% (95% CI: 72.8–79.5%), I2 = 59% (Fig. 8).
There was considerable heterogeneity between findings,
which varied from 51% to 90% and may reflect multiple
causes. Although findings are imprecise there was no
evidence that one procedure produced higher levels of
satisfaction than another.
Disease-specific and generic QoL scoring instruments
were used less often including PAC QoL (11 studies,
data not shown), EQ-VAS (six studies, data not
shown), EQ-5D (two studies, data not shown), FIQL
(one study, data not shown). Using such instruments,
improvements in QoL were associated with symptom
improvements in most studies except for Ribaric et al.
[56] who showed non-significant improvements in EQ-
5D and EQ VAS in 100 patients 12 months after Con-
tour Transtar and Madbouly et al. [29] who, reporting
on 46 patients after PPH01, showed significant
improvements in PAC QoL at 18 months but not at
42 months.
The aim of rectal excision procedures is to enable
normal evacuation and assessment of constipation symp-
toms is therefore the most important outcome. How-
ever, many patients also suffer from incontinence, either
as a result of neurogenic/traumatic sphincter patholo-
gies or from the effects of a high grade recto-anal intus-
susception. Instrumented excisional procedures are
postulated to increase the risk of faecal incontinence by
their very nature. Indeed one of the exclusion criteria in
many studies was greater than minor faecal incontinence
(Table S1). Objective scores (Wexner or St Marks
incontinence score, FISI) when reported (Table 6)
showed either no change or reduction in scores other
than in one study where an increase was reported [47].
In this study after PPH01, the median Wexner inconti-
nence score rose from 3.3 to 5.5 after 2–3 years. It was
reported that a third of patients developed incontinence
symptoms 1–4 years after the procedure.
While anatomical outcome is necessarily only a surro-
gate of clinical outcomes, recurrent prolapse was
reported for less than half of cohorts and occurred in
4.3% of patients (95% CI: 2.0–7.3%), I2 = 78%. Again
findings were heterogeneous and there was no robust
evidence that one procedure was associated with higher
long term adverse outcomes than another. One RCT
comparing STARR with Contour Transtar reported that
at three years post-procedure 12% of STARR patients
had a clinical recurrence compared with none of the
Contour Transtar patients (P = 0.035) [37]. The
weight of resected tissue was significantly greater in the
Transtar group.
Summary evidence statements: efficacy
1 Data on efficacy were inconsistently measured and
findings heterogeneous, making estimates tentative
and imprecise (level IV).
2 Although inconsistent, patient global satisfaction rat-
ings typically suggest (at least) satisfactory outcome
in about 73–80% of patients (level II).
3 Although inconsistent, a reduction of 53–91% in
Longo scoring system for obstructive defecation syn-
drome occurred in about 68–76% of patients (level II).
Table 5 Percentage success based on global satisfaction ratings
(GSR).
Author Year N FU mean GSR %*
(a) PPH01
Boccasanta [15] 2004 25 23 88
Boccasanta [16] 2004 90 16 90
Dindo [20] 2008 24 18 83
Isbert [27] 2010 68 12 80
Reboa [25] 2009 33 18 75.7
Zehler [32] 2010 20 66 80
Goede [33] 2011 344 12 81
Patel [36] 2011 37 20 71.9
Boccasanta [37] 2011 50 36 66
Song [39] 2011 58 34 63.4
Renzi [41] 2011 30 36 60
Biviano [8] 2011 30 38 60
Kohler [47] 2012 80 39 77.5
Hasan [48] 2012 40 12 75
Adams [50] 2013 37 13 50
Zhang [53] 2013 75 30 64
Panicucci [54] 2014 54 † 12 87
Borie [55] 2014 25 18 84
Leardi [58] 2014 51 36 81
(b) PPH03
Jiang [45] 2012 43‡ 12 72
Gentile [57] 2014 30 12 73§
(c) Contour Transtar
Lenisa [3] 2009 75 12 77.3
Isbert [27] 2010 82 12 81.5
Martellucci [35] 2011 133 19 69.8
Bock [52] 2013 70 48 87
(d) Intra-anal Delorme’s procedure
Liberman [14] 2000 34 43 76.4
Ganio [49] 2013 167 36 78.2¶
Gentile [57] 2014 36 12 73**
*Proportion good or excellent.
†18 patients had Contour Transtar.
‡linear stapler.
§GSR is based on 66 patients (36 had intra-anal Delorme’s).
¶91 patients also had levatoroplasty.
**GSR is based on 66 patients (30 had PPH03).
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Table 6 Functional outcomes by procedure.
Author Year N FU‡‡
% reduction
in CCS
% reduction
in Longo/
ODS score
% reduction
in SSS score
Any significant
increase or
decrease in
FI scores
(a) PPH01
Boccasanta [15] 2004 25 23 68.6 \ \ N
Boccasanta [16] 2004 90 16 65.3 \ \ N
Arroyo [18] 2007 17 24 \ \ 68 \
Gagliardi [19] 2008 85 * 17 \ \ \ \
Dindo [20] 2008 24 18 54.5 \ \ \
Lehur [21] 2008 119 12 \ 71 \ \
Arroyo [22] 2008 37†† 26 62.3 \ \ \
Boccasanta [26] 2010 74 24 \ 88.4 \ \
Harris [23] 2009 36 12 \ 88 \ \
Isbert [27] 2010 68 12 46.8 65.5 \ N
Jayne [24] 2009 2224† 12 \ 67.3 76.1 Decrease
Reboa [25] 2009 33 18 72.4 \ \ \
Zhang [28] 2010 50 12 63.5 66.3 70.3 \
Madbouly [29] 2010 46 42 \ 75.3 \ \
Schwandner [30] 2010 379 12 \ \ 49.4 N
Ram [31] 2010 30 26 \ \ \ \
Zehler [32] 2010 20 66 \ 65 40 Decrease
Goede [33] 2011 344 12 \ 89 \ Decrease
Meurette [34] 2011 30 48 \ 58.6 \ N
Patel [36] 2011 37 20 \ 58.6 \ \
Boccasanta [37] 2011 50 20 \ 83 \ N
Stuto [38] 2011 2171§ 12 \ 70 \ Decrease
Song [39] 2011 58 34 58.5 \ \ \
Ding [40] 2011 86 12 \ 60.5 \ N
Renzi [41] 2011 30 36 \ 59.6 \ \
Reibetanz [42] 2011 170‡ 18 47 \ \ \
Naldini [43] 2011 15 24 \ 73.4 \ \
Biviano [8] 2011 30 38 76.1 \ \ \
Savastano [44] 2012 32 27 \ 87 \ \
Boenicke [46] 2012 181¶ 19 58.9 \ \ N
Kohler [47] 2012 80 39 54.8 \ \ Increase
Hasan [48] 2012 40 12 83.8 \ \ \
Adams [50] 2013 37 13 \ \ \ \
Zhang [53] 2013 75 30 54.6 53.5 \ N
Panicucci [54] 2014 54 ** 12 68.5 74.4 \ \
Borie [55] 2014 25 18 \ 59 \ \
Leardi [58] 2014 51 36 \ 76 \ Decrease
(b) PPH03
Arroyo [18] 2007 20 24 \ \ 68 \
Arroyo [22] 2008 67R 26 62.3 \ \ \
Jiang [45] 2012 43 12 62.9 \ \ \
Gentile [57] 2014 30 12 \ \ \ \
(c) Contour Transtar
Lenisa [3] 2009 75 12 \ 83 50.2 N
Isbert [27] 2010 82 12 50 68 \ N
Martellucci [35] 2011 133 19 48 \ \ \
Boccasanta [37] 2011 50 36 \ 85 \ N
Renzi [41] 2011 31 24 \ 64.5 \ \
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4 Evidence for longer term benefits persisting from
procedures is sparse but suggests improvements may
be maintained (level II).
5 Findings from efficacy measures provided insufficient
evidence to recommend one type of procedure over
another (level IV).
6 The use of Contour Transtar increases the amount of
resected tissue and may reduce recurrence rates
although this requires further study (level IV).
7 There is no evidence that rectal excisional procedures
contribute towards post-operative faecal incontinence
(level II).
8 Recurrent prolapse occurred in 4.3% of patients con-
sidering all studies (level IV); rates were lower (1.7%)
in higher quality studies (level II).
Variation in outcomes by level of evidence
Meta-analytic findings are reported for each of the out-
comes reported, subdivided by level of evidence
(Table 7). Recurrent prolapse was the only adverse out-
come where findings varied by grade of evidence: grade
IB/IIB: 1.7% of patients (95% CI: 0.4–3.7%), I2 = 54%,
and grade IV: 9.2% of patients (95% CI: 4.1–15.9%),
I2 = 78%.
Patient selection
Patient selection is generally perceived to be essential
when choosing a surgical approach. Whilst rectal exci-
sion procedures may be efficient at correcting normal
anatomy, there may be many underlying functional and
organic pathologies that mean surgery is unsuccessful at
‘curing’ the patient [59]. It is advised when contem-
plating a surgical approach to exhaust first all forms of
conservative or medical management. Forty-one out of
55 cohorts studied highlight the fact that all patients
had undergone a period of conservative management
(Table 7).
Many of the current studies reference inclusion and
exclusion criteria based upon a previous consensus con-
ference [60], namely that patients should be selected on
the basis of recognized symptoms of ODS with evi-
dence of anatomical defects on defaecography (recto-
coele and/or internal rectal prolapse) and adequate anal
sphincter function (at least assessed by digital rectal
Table 6 (Continued).
Author Year N FU‡‡
% reduction
in CCS
% reduction
in Longo/
ODS score
% reduction
in SSS score
Any significant
increase or
decrease in
FI scores
Naldini [43] 2011 15 24 \ 69.9 \ \
Savastano [44] 2012 32 27 \ 90.3 \ \
Masoni [51] 2013 187 12 67 \ \ \
Bock [52] 2013 70 48 \ 56.3 46.7 N
Ribaric [56] 2014 100 12 \ 64.7 \ N
(d) Intra-anal Delorme’s procedure
Liberman [14] 2000 34 43 \¶¶ \ \ N
Pescatori [17] 2006 26 36 \ \ \ \
Ganio [49] 2013 167 *** 36 66.7 63.5 \ N
Gentile [57] 2014 36 12 \ \ \ \
N, no change; \, not recorded; FI, faecal incontinence.
All PPH03, except Jiang [45] translinear stapler.
*Report on 123 patients, but only 85 operated on.
†Report on 2838 patients, but 2224 reached 12 months follow-up; complete data for ODS score (41%), complete data for SSS (57%).
‡101 patients had Countour Transtar.
§208 patients had Contour Transtar, 1485 patients completed 12 months follow-up.
¶Some patients had Contour Transtar.
**18 patients had Contour Transtar.
††Complications are reported for 104 patients (67 had PPH03).
‡‡Mean follow-up in months.
§§This study also showed a significant improvement in the Knowles-Eccersley-Scott-Symptom (KESS) score.
¶¶67–93% of patients showed improvement in 4 of CCS domains.
***91 patients also had levatoroplasty.
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examination). In 42 out of the 55 cohorts studied,
patients had at least 3 ODS symptoms (Table 8). In
general when selecting patients for functional surgery it
has also been advised to select patients with a high
symptom load [61]. A criticism made to the authors of
the European STARR Registry (n = 2224) was that the
median ODS score was low (15.7 out of a possible 40)
and that the range was high (1–31) [24]. The two level
I RCTs reported inclusion criteria of an ODS score
> 12 in one [41] and 15 in the other [37]. The major-
ity of studies reported an inclusion criterion of rectal
intussusception and/or rectocoele, (38 out of 55 study
groups). Thirty-two out of the 55 study groups
reported a rectocoele > 2 cm, and in 26 of these, more
than 75% of patients had a rectocele > 2 cm. Thirty-
seven out of the 55 study groups reported on recto-rec-
tal or recto-anal intussusception, and in 28 of these
more than 60% of patients had an intussusception. Mul-
tiple classifications were used for diagnosing an intussus-
ception including Pescatori [62], Shorvon [63], and
Oxford [64]. Other studies stated that inclusion
required a rectal intussusception greater than 10 mm
[41] or recto-anal intussusception > 10 mm [31]. One
study reported on outcome at five years following
PPH01 for patients with a symptomatic rectocoele
when the authors specifically excluded intussusception
[32]. This study found an 80% satisfaction rate at one
year, which remained at five years. It was not possible
to draw conclusions regarding efficacy according to
either the presence of an intussusception (whichever
grade/stage) or rectocoele size.
It is pertinent to discuss exclusion criteria as this may
influence the surgeon in their choice of procedure (rein-
forcement/suspension/excision). Reference was again
made in many studies to the consensus statement [60]
and a decision making algorithm for STARR [65] when
defining exclusion criteria. Specifically, external rectal
prolapse, solitary rectal ulcer syndrome (SRUS),
anatomical enterocele, and ‘significant gynaecological
pelvic floor abnormality requiring treatment’ were
Figure 7 Forest plot showing reduction
in Longo’s obstructed defacation
syndrome (ODS) score by operation
type.
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stated as exclusions. Less than 50% of the reviewed
studies excluded external rectal prolapse or other pelvic
organ prolapse, and no study excluded SRUS
(Table S1). Only one study graded pelvic organ pro-
lapse (rectocoele, cystocoele, vault, uterine) with a stan-
dardized grading system e.g. POP-Q (data not shown)
[26]. Whilst it is sensible to exclude patients with exter-
nal rectal prolapse, no conclusion can be made regard-
ing excluding patients with SRUS, or concomitant
pelvic organ prolapse.
Anatomical enterocoele is generally regarded as a
contraindication to an anterior rectal wall excision
[60,65], however many studies did not exclude this
(Table S1). Irrespective of this, there were no cases of
iatrogenic small bowel injury reported. One study
examined the outcome with respect to harms in
patients with a functional enterocoele, and those with-
out [42]. All patients had either PPH01 or Contour
Transtar and outcomes with respect to harms were
similar.
Summary evidence statements: patient selection
1 Patient selection, although perceived as vital in pre-
dicting outcome, is inconsistently documented and
poorly informed by current evidence (level IV).
2 Patients with at least three ODS symptoms together
with a rectocoele with or without an intussusception,
who have failed conservative management may bene-
fit from a rectal excisional procedure (level II).
3 It is not possible to advise on excluding patients with
concomitant pelvic organ prolapse or SRUS when
considering a rectal excisional procedure (level IV).
Conclusions
A systematic review of evidence for the perioperative
and long term benefits and harms of rectal excisional
procedures identified a modest number of high quality
studies together with a larger number of observational
lesser quality studies. Whilst the evidence is superior to
the level of evidence for other procedures for
Figure 8 Forest plot showing global
satisfaction rating (%) by operation type.
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constipation it is still rather poor in the field of medi-
cine systematic reviews. Notwithstanding this, certain
conclusions can be drawn:
1 In the presence of a rectocoele with or without an
intussusception, together with at least three symp-
toms of ODS, a rectal excisional procedure may ben-
efit the patient after all conservative measures have
been exhausted.
2 Reliance on proving efficacy using GSR and unvali-
dated scoring systems (Longo) is not satisfactory and
greater emphasis should be placed in future studies
on the use of disease-specific and generic QoL scor-
ing instruments.
3 It is not possible to advise which excisional technique
is superior from the point of view of efficacy, peri-
operative variables, or harms (peri-operative or long
term adverse outcomes). Future study is required.
4 Both short- and long-term harms may have been
exaggerated in previous reports. Rectal excisional
procedures appear to be safe with little major mor-
bidity. Rectal urgency appears to be a problem, but
findings are inconsistent because of poor reporting.
5 Despite evidence of mixed grade (IB, IIB and IV)
being available for rectal excision procedures, there
was little evidence that outcomes varied by grade of
evidence. Recurrent prolapse was the only adverse
outcome where findings varied by grade of evidence
and thus may be a chance finding in the absence of
any systematic pattern across outcomes.
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Table 7 Outcomes by level of evidence.
IB/IIB IV Combined
IB/IIB
vs IV
Effect size (95%CI), I2 Effect size (95%CI), I2 Effect size (95%CI), I2 p
Perioperative data
Procedure duration (mins) 44.3 (39.9–48.7), 99.2% 44.4 (35.4–53.5), 99.5% 44.3 (40.5–48.1), 99.5% 0.98
Length of stay (days) 2.8 (2.5–3.2), 98.1% 3.6 (2.5–4.7), 98.7% 3.0 (2.6–3.4), 98.8% 0.18
Total complication rate (%) 13.5% (8.3–19.6%), 94.0% 22.0% (15.9–28.7%), 85.5% 16.9% (12.7–21.5%), 92.6% 0.052
Perioperative harm
Bleeding rate (%) 1.5% (0.7–2.4%), 52.7% 2.2% (0.6–4.3%), 72.4% 1.6% (0.9–2.5%), 63.0% 0.56
Sepsis rate (%) 0.0% (0.0–0.5%), 67.1% 0.8% (0.0–2.2%), 48.8% 0.2% (0.0–0.7%), 62.6% 0.090
Anastomotic
dehiscence rate (%)
0.2% (0.0–0.9%), 67.3% 0.2% (0.0–0.9%), 11.2% 0.3% (0.0–0.8%), 61.6% 0.98
Long term adverse outcomes
Rectal stenosis (%) 0.1% (0.0–0.5%), 24.4% 0.4% (0.0–1.2%), 36.4% 0.2% (0.0–0.6%), 30.3% 0.52
Rectal pain (%) 0.6% (0.0–1.9%), 83.6% 0.8% (0.1–1.8%), 0.0% 0.7% (0.1–1.6%), 78.7% 0.76
Rectal urgency (%) 5.6% (2.7–9.3%), 90.7% 4.2% (0.9–9.2%), 89.1% 5.2% (2.7–8.2%), 91.8% 0.51
Rectal prolapse (%) 1.7% (0.4–3.7%), 53.9% 9.2% (4.1–15.9%), 82.0% 4.3% (2.0–7.3%), 78.7% 0.006
Efficacy
Global satisfaction
rating (%)
76.4% (71.3–81.1%), 59.0% 76.0% (71.1–80.7%), 62.4% 76.3% (72.8–79.5%), 59.0% 0.94
Longo ODS (%) 71.9% (68.5–75.1%), 70.7% 71.3% (58.0–83.0%), 90.9% 72.2% (68.5–75.8%), 83.2% 0.93
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Table 8 Inclusion criteria for procedures.
Author Year N
Rectocele
> 2 cm %
Recto-rectal /
Recto-anal
Intussusception %
Rectocele +
Intussusception %
Failure of
conservative RX
At least 3
ODS symptoms
(a) PPH01
Boccasanta [15] 2004 25 100 100 100 Yes Yes
Boccasanta [16] 2004 90 97 100 97 Yes Yes
Arroyo [18] 2007 17 92 27 NR Yes Yes
Gagliardi [19] 2008 85* 80 93 73 Yes Yes
Dindo [20] 2008 24 79 83 NR Yes Yes
Lehur [21] 2008 119 92 61 NR No Yes
Arroyo [22] 2008 37†† NR NR NR Yes Yes
Boccasanta [26] 2010 74 100 100 100 Yes Yes
Harris [23] 2009 36 81 39 39 No Yes
Isbert [27] 2010 68 100 80 80 Yes Yes
Jayne [24] 2009 2224† 99 80 NR Yes Yes
Reboa [25] 2009 33 67 97 NR Yes Yes
Zhang [28] 2010 50 NR NR NR No No
Madbouly [29] 2010 46 59 41 NR Yes Yes
Schwandner [30] 2010 379 NR NR NR No Yes
Ram [31] 2010 30 67 13 67 No Yes
Zehler [32] 2010 20 100 0 0 Yes Yes
Goede [33] 2011 344 NR 100 NR No Yes
Meurette [34] 2011 30 100 100 100 Yes No
Patel [36] 2011 37 100 81 81 Yes Yes
Boccasanta [37] 2011 50 100 100 100 No Yes
Stuto [38] 2011 2171§ 82 95 NR No Yes
Song [39] 2011 58 62 80 NR Yes Yes
Ding [40] 2011 86 90 94 77 Yes Yes
Renzi [41] 2011 30 NR NR NR Yes Yes
Reibetanz [42] 2011 170‡ NR NR NR No No
Naldini [43] 2011 15 NR NR NR Yes Yes
Biviano [8] 2011 30 77 50 NR Yes Yes
Savastano [44] 2012 32 NR NR NR No No
Boenicke [46] 2012 181¶ NR NR 100 Yes Yes
Kohler [47] 2012 80 100 100 NR No Yes
Hasan [48] 2012 40 90 55 NR Yes Yes
Adams [50] 2013 37 NR NR NR Yes Yes
Zhang [53] 2013 75 NR 87 NR Yes No
Panicucci [54] 2014 54 ** NR NR NR Yes Yes
Borie [55] 2014 25 100 65 65 Yes Yes
Leardi [58] 2014 51 43 57 0 Yes No
(b) PPH03
Arroyo [18] 2007 20 92 27 NR Yes Yes
Arroyo [22] 2008 67§§ NR NR NR Yes Yes
Jiang [45] 2012 43 100 56 56 Yes Yes
Gentile [57] 2014 30 NR NR NR Yes No
(c) Contour Transtar
Lenisa [3] 2009 75 NR NR NR Yes Yes
Isbert [27] 2010 82 100 65 65 Yes Yes
Martellucci [35] 2011 133 NR NR NR Yes Yes
Boccasanta [37] 2011 50 100 100 100 No Yes
Renzi [41] 2011 31 NR NR NR Yes Yes
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